IMD business school for management and leadership courses

Roche is deploying artificial intelligence across its value chain to accelerate drug discovery, enhance diagnostics, and optimize pharmaceutical manufacturing. AI enables Roche to decode complex biological relationships, improve clinical decision-making, and personalize treatment with greater accuracy and speed. Through predictive models, continuous lab-data feedback loops, and partnerships with AWS and Nvidia, Roche advances a “lab-in-the-loop” approach to drug development, reducing trial-and-error and increasing R&D efficiency. 

In 2025, Roche announced the appointment of Wafaa Mamilli as Chief Digital Technology Officer to lead global digital strategy, furthering the company’s commitment to AI-driven transformation. Roche also launched the Roche Genentech Innovation Center Boston to focus on AI and data science for cardiovascular, renal, and metabolic diseases. In diagnostics, Roche partnered with Prenosis to integrate the FDA-cleared Sepsis Immunoscore into its Navify® platform and expand digital pathology capabilities through AI collaborations aimed at cancer diagnostics. 

Roche grounds these innovations in ethics. Its AI Principles prioritize transparency, human oversight, and sustainability. The company deepened its ethical commitment through a strategic partnership with IIT Madras’ Centre for Responsible AI to help shape policy and accountability frameworks.